Augmedix Inc (NASDAQ: AUGX)’s stock price has gone decline by -6.64 in comparison to its previous close of 2.71, however, the company has experienced a -11.23% decrease in its stock price over the last five trading days. InvestorPlace reported 2024-04-19 that Let’s just get something straight off the bat – penny stocks to rebound are risky. They’re incredibly treacherous in terms of both short-term downside and longer-term damage to your portfolio.
Is It Worth Investing in Augmedix Inc (NASDAQ: AUGX) Right Now?
The 36-month beta value for AUGX is at 0.53. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AUGX is 43.96M, and currently, shorts hold a 2.82% of that float. The average trading volume for AUGX on May 02, 2024 was 366.66K shares.
AUGX’s Market Performance
The stock of Augmedix Inc (AUGX) has seen a -11.23% decrease in the past week, with a -37.06% drop in the past month, and a -42.76% fall in the past quarter. The volatility ratio for the week is 6.99%, and the volatility levels for the past 30 days are at 7.15% for AUGX. The simple moving average for the past 20 days is -25.96% for AUGX’s stock, with a -45.82% simple moving average for the past 200 days.
Analysts’ Opinion of AUGX
Many brokerage firms have already submitted their reports for AUGX stocks, with B. Riley Securities repeating the rating for AUGX by listing it as a “Buy.” The predicted price for AUGX in the upcoming period, according to B. Riley Securities is $5.50 based on the research report published on April 03, 2024 of the current year 2024.
Evercore ISI, on the other hand, stated in their research note that they expect to see AUGX reach a price target of $6. The rating they have provided for AUGX stocks is “In-line” according to the report published on December 15th, 2023.
AUGX Trading at -33.04% from the 50-Day Moving Average
After a stumble in the market that brought AUGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.52% of loss for the given period.
Volatility was left at 7.15%, however, over the last 30 days, the volatility rate increased by 6.99%, as shares sank -39.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.47% lower at present.
During the last 5 trading sessions, AUGX fell by -11.23%, which changed the moving average for the period of 200-days by -37.68% in comparison to the 20-day moving average, which settled at $3.33. In addition, Augmedix Inc saw -56.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUGX starting from Shakil Ian, who sale 500 shares at the price of $3.80 back on Apr 15 ’24. After this action, Shakil Ian now owns 3,000 shares of Augmedix Inc, valued at $1,900 using the latest closing price.
Shakil Ian, the CHIEF STRATEGY OFFICER of Augmedix Inc, sale 19,544 shares at $3.82 during a trade that took place back on Apr 12 ’24, which means that Shakil Ian is holding 3,000 shares at $74,590 based on the most recent closing price.
Stock Fundamentals for AUGX
Current profitability levels for the company are sitting at:
- -0.43 for the present operating margin
- 0.48 for the gross margin
The net margin for Augmedix Inc stands at -0.43. The total capital return value is set at -0.45. Equity return is now at value -154.68, with -38.21 for asset returns.
Based on Augmedix Inc (AUGX), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -0.71. The debt to equity ratio resting at 0.93. The interest coverage ratio of the stock is 20.07.
Currently, EBITDA for the company is -17.68 million with net debt to EBITDA at 1.11. When we switch over and look at the enterprise to sales, we see a ratio of 2.31. The receivables turnover for the company is 5.23for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.41.
Conclusion
In conclusion, Augmedix Inc (AUGX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
